Rationale and design of a UK database for a rare cancer type: The GEM Registry for gastrointestinal stromal tumours

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1403-1407

  Bulusu, V R ^a   Fullarton, J ^b   Leahy, M ^c   Morgan, C ^d   Rasheed, A ^e   Taniere, P ^f   Toh, S ^g   Verrill, M ^h   White, J ⁱ   Judson, I ^j  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b Strategen Ltd   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

^e ROYAL GWENT HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^g QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL PRACTICE; DATA BASE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INCIDENCE; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; SUMMER; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; DATA COLLECTION; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; PREVALENCE; REGISTRIES; TREATMENT OUTCOME;

EID: 84884596338     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.406     Document Type: Article

References (23)

1. Brabec P, Sufliarsky J, Linke Z, Plank L, Mrhalova M, Pavlik T, Klimes D, Gregor J (2009) A whole population study of gastrointestinal stromal tumours in the Czech Republic and Slovakia. Neoplasma 56(5): 459-464.
2. Burkill GJC, Badran M, Al-Muderis O, Thomas JM, Judson IR, Fisher C, Moskovic EC (2003) Malignant gastrointestinal stromal tumor: Distribution, imaging features, and pattern of metastatic spread. Radiology 226(2): 527-532.
3. Call J, Walentas CD, Eickhoff JC, m Scherzer N (2012) Survival of gastrointestinal stromal tumor in the imatinib era: Life raft group observational registry. BMC Cancer 12: 90.
4. Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer 11(12): 865-878.
5. Chacon M, Reichardt P, Gu J, Nishida T, Barrios CH, Blay J, Reichardt A, Blackstein ME, Casali PG, Kang Y (2010) The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST-Second annual summary. J Clin Oncol 28(15s): Abstr no 10092.
6. DeMatteo RP, Lewis JJ, Leung D, Mudan SS (2000) Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 231(1): 51-58.
7. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368(9544): 1329-1338.
8. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33(5): 459-465.
9. Gliklich RE, Dreyer NA (2010) Registries for Evaluating Patient Outcomes: A User's Guide. 2nd edn (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. d/b/a Outcome] under Contract No. HHSA29020050035I TO3.) AHRQ Publication No.10-EHC049) Agency for Healthcare Research and Quality: Rockville, MD, USA
10. Heinrich MC (2010) Imatinib treatment of metastatic GIST; don't stop (believing). Lancet Oncol 11(10): 910-911.
11. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain of function mutations of c-kit in human gastrointestinal stromal tumours. Science 279(5350): 577-580.
12. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14): 1052-1056.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS, Kang DY. Gastrointestinal Stromal Tumor Committee; Korean Gastrointestinal Pathology Study Group (2005) Gastrointestinal stromal tumors in Koreans: Its incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci 20(6): 977-984.
14. Kim SY, Janeway K, Pappo A (2010) Pediatric and wildtype gastrointestinal stromal tumour (GIST): New therapeutic approaches. Curr Opin Oncol 22(4): 347-350.
15. Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438(1): 1-12.
16. Miettinen M, Lasota J (2006a) Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130(10): 1466-1478.
17. Miettinen M, Lasota J (2006b) Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 23(2): 70-83.
18. National Institute for Clinical Excellence (2004) Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours. Available at www.nice.org.uk/nicemedia/live/11548/32969/32969.pdf (Accessed February 2013
19. National Institute for Health and Clinical Excellence (2009) Sunitinib for the treatment of gastrointestinal stromal tumours. Available at www.nice. org.uk/nicemedia/pdf/TA179Guidance.pdf (Accessed February 2013
20. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG (2005) Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103(4): 821-829.
21. Pisters PWT, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC. reGISTry Steering Committee (2011) A USA registry of gastrointestinal stromal tumor patients: Changes in practice over time and differences between community and academic practices. Ann Oncol 22(11): 2523-2529.
22. Tryggvason G, Gislason HG, Magnusson MK, Jónasson JG (2005) Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117(2): 289-293.
23. West R, Cohen C, Xin C, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Surg Path 165(1): 107-113.